- Home
- INCY vs BAH Comparison
INCY vs BAH Comparison
Compare INCY & BAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- BAH
- Stock Information
- Founded
- INCY 1991
- BAH 1914
- Country
- INCY United States
- BAH United States
- Employees
- INCY N/A
- BAH N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- BAH Professional Services
- Sector
- INCY Health Care
- BAH Consumer Discretionary
- Exchange
- INCY Nasdaq
- BAH Nasdaq
- Market Cap
- INCY 13.4B
- BAH 13.9B
- IPO Year
- INCY 1993
- BAH 2010
- Fundamental
- Price
- INCY $68.46
- BAH $99.95
- Analyst Decision
- INCY Hold
- BAH Hold
- Analyst Count
- INCY 20
- BAH 11
- Target Price
- INCY $73.81
- BAH $137.40
- AVG Volume (30 Days)
- INCY 2.1M
- BAH 2.6M
- Earning Date
- INCY 07-29-2025
- BAH 07-25-2025
- Dividend Yield
- INCY N/A
- BAH 2.20%
- EPS Growth
- INCY N/A
- BAH 57.95
- EPS
- INCY 0.10
- BAH 7.25
- Revenue
- INCY $4,413,226,000.00
- BAH $11,980,000,000.00
- Revenue This Year
- INCY $13.29
- BAH $3.69
- Revenue Next Year
- INCY $10.47
- BAH $4.89
- P/E Ratio
- INCY $623.03
- BAH $13.79
- Revenue Growth
- INCY 17.13
- BAH 12.36
- 52 Week Low
- INCY $53.56
- BAH $99.13
- 52 Week High
- INCY $83.95
- BAH $190.59
- Technical
- Relative Strength Index (RSI)
- INCY 56.95
- BAH 32.13
- Support Level
- INCY $67.57
- BAH $100.81
- Resistance Level
- INCY $71.29
- BAH $103.73
- Average True Range (ATR)
- INCY 1.98
- BAH 2.65
- MACD
- INCY -0.13
- BAH 0.01
- Stochastic Oscillator
- INCY 61.55
- BAH 11.85
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About BAH Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.